Table 1.
Patient characteristics shown in subgroups.
| Subgroups | N | % |
|---|---|---|
| Total | 14,485 | 100.0 |
| Age | ||
| 20–49 yr | 4140 | 28.6 |
| 50–59 yr | 3903 | 27.0 |
| 60–69 yr | 3746 | 25.9 |
| 70–79 yr | 1674 | 11.6 |
| ≥80 yr | 1022 | 7.1 |
| Ethnicity | ||
| New Zealand European | 10,727 | 74.1 |
| Māori | 1377 | 9.5 |
| Pacific Peoples | 863 | 6.0 |
| Asian | 1190 | 8.2 |
| Other/Unknown | 328 | 2.3 |
| NZDep2013 | ||
| NZDep 1–2 (least deprived) | 2582 | 17.8 |
| NZDep 3–4 | 2833 | 19.6 |
| NZDep 5–6 | 2901 | 20.0 |
| NZDep 7–8 | 2177 | 15.0 |
| NZDep 9–10 (most deprived) | 2105 | 14.5 |
| Unknown | 1887 | 13.0 |
| Region | ||
| Auckland | 7962 | 55.0 |
| Christchurch | 2354 | 16.3 |
| Waikato | 2175 | 15.0 |
| Wellington | 1994 | 13.8 |
| Facility | ||
| Private | 5004 | 34.6 |
| Public | 9481 | 65.5 |
| Screen-detected | ||
| No | 8325 | 57.5 |
| Yes | 6160 | 42.5 |
| Previous hospitalisation (which indicate severe comorbidities) | ||
| No | 8138 | 56.2 |
| Yes | 6347 | 43.8 |
| Time from diagnosis to first cancer treatment | ||
| <31 days | 8227 | 56.8 |
| 31–62 days | 5215 | 36.0 |
| >62 days | 1043 | 7.2 |
| Histology | ||
| Ductal | 11,170 | 77.1 |
| Lobular | 1683 | 11.6 |
| Mixed | 406 | 2.8 |
| Other and Unknown | 1226 | 8.5 |
| Anatomic stage | ||
| I | 6735 | 46.5 |
| II | 5119 | 35.3 |
| III | 1919 | 13.3 |
| IV | 291 | 2.0 |
| Unknown | 421 | 2.9 |
| Histologic grade | ||
| 1 | 3267 | 22.6 |
| 2 | 6534 | 45.1 |
| 3 | 4300 | 29.7 |
| Unknown | 384 | 2.7 |
| Biological subtype | ||
| HR+ HER2− | 9954 | 68.7 |
| HR− HER2+ | 736 | 5.1 |
| Triple-negative | 1498 | 10.3 |
| Triple-positive | 1283 | 8.9 |
| Unknown | 1014 | 7.0 |
HR = hormone receptor; HR+ refers to presence of estrogen receptor (ER) and/or progesterone receptor (PR); HR− refers to absence of estrogen receptor (ER) and progesterone receptor (PR).